

This announcement is not an offer to purchase, a solicitation of an offer to purchase, an offer to sell, or a solicitation of an offer to sell the FCC Bonds. This announcement does not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law. This announcement is not for release, publication or distribution in or into, or to any person resident and/or located in, any jurisdiction where such release, publication or distribution is unlawful.

This announcement does not constitute an offer to sell or the solicitation of an offer to purchase any securities in the United States, India or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus which will contain detailed information about the Company and its management, as well as its financial statements. No public offering of securities is to be made by the Company in the United States.

15 September, 2021

To, Dy. General Manager Department of Corporate Services, BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai – 400 001 Ref: Scrip Code: 532296	To, The Manager – Listing National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Ref: Scrip Name: GLENMARK
--	---

Dear Sirs,

Re: Intimation of buyback by Glenmark Pharmaceuticals Limited (the "Company") in respect of the outstanding US\$76,750,000 2.00% Resetable Onward Starting Equity-Linked Securities due 2022 (the "FCC Bonds")

The Company had issued the FCC Bonds in 2016 which are currently listed on the Singapore Exchange Securities Trading Limited. The Company has purchased an aggregate principal amount of US\$ 1,000,000 of the FCC Bonds at repurchase price of 120.30% of the principal amount at an aggregate purchase price of US\$ 1,203,000.00 plus accrued but unpaid interest and additional interest. Pursuant to the aforementioned repurchase, an aggregate principal amount of US\$ 75,750,000 of the FCC Bonds currently remain outstanding.

We request you to take this on record, and to treat the same as compliance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited



**Harish Kuber
Company Secretary and Compliance Officer**



Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com